Atlantic Health System Cancer Care will continue its tradition of world-class medical education with its 2020 Annual Review in Oncology Virtual Symposium.  The symposium, held virtually this year with free registration, will take place Saturday, June 27, 2020, from 8 a.m. to 12:30 p.m. ET.  Distinguished faculty from some of the Northeast’s leading cancer centers will summarize the latest advances in oncology, which have recently been presented at international conferences.  The diverse range of topics should be of interest to surgeons, medical and radiation oncologists and other physicians, nurses and allied health professionals.

Missak Haigentz, Jr., MD,  medical director of hematology and oncology for Atlantic Health System and principal investigator for the Atlantic Health Cancer Consortium, the only New Jersey-based National Cancer Institute Community Oncology Research Program (NCORP), will moderate.

“Medical education in the era of COVID-19 is more important than ever,” said Dr. Haigentz.  “Oncology education for physicians and other health care professionals has continued at Morristown Medical Center and Atlantic Health System, and we remain the ‘go-to’ destination — whether it’s in-person or online — for oncology medical education with some of the nation’s top cancer researchers.”

Sign Up for Sparta Newsletter
Our newsletter delivers the local news that you can trust.

Dr. Haigentz is an internationally known expert in lung and head and neck cancers, including thyroid cancer.  He has served as lead or co-author on numerous studies, and is currently principal investigator at Atlantic Health System for 13 lung cancer studies and eight head and neck cancer clinical trials.  

Dr. Haigentz will welcome symposium attendees, before introducing the presenters:

  • David H. Ilson, MD, PhD, attending physician, Memorial Sloan Kettering Cancer Center, New York City, will speak on advances in gastrointestinal cancers. Dr. Ilson is a medical oncologist with special interest and expertise in treating patients who have upper gastrointestinal cancers, particularly those with esophageal cancer. His research focus is studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat locally advanced disease. (8:15 - 9:15 a.m.)
  • Hossein Borghaei, DO, MS, professor and chief, thoracic oncology and The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, will present advances in treating thoracic malignancies. Dr. Borghaei believes in a team approach to the care of patients with lung cancer. His laboratory concentrates on the development of new cancer treatments with an emphasis on the use of immunotherapy and monoclonal antibodies. He has served as investigator or co-investigator for groundbreaking trials of immunotherapy for patients with lung cancer (9:20 - 10:20 a.m.)
  • Benjamin A. Gartrell, MD, director of genitourinary oncology and associate professor, Department of Medicine (Oncology) and Urology, Montefiore Einstein Center for Cancer Care, Bronx, NY, who will cover genitourinary cancers.  His expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. Dr. Gartrell focuses on clinical and translational research, with current interests in the significance of a novel immune checkpoint molecule in bladder cancer, the role of the autonomic nervous system in prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. (10:25 - 11:25 a.m.)
  • Deborah Toppmeyer, MD, chief medical officer and chief of medical oncology and director, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, New Brunswick, will provide an update on breast cancer research. Dr. Toppmeyer’s clinical interests include breast cancer, young women with breast cancer, and cancer genetics.  She has led many clinical trials and has served as a co-investigator on the NCI-sponsored TAILORx trial, which found that for women with hormone receptor-positive, HER2-negative, axillary lymph node­–negative breast cancer, treatment with chemotherapy and hormone therapy after surgery is not more beneficial than treatment with hormone therapy alone. (11:30 a.m. – 12:30 p.m.)

The program’s learning objectives are for participants to be able to:

  • More accurately diagnose and effectively treat various types of cancer, including thoracic, breast, gastrointestinal and genitourinary;
  • Describe highlighted clinical trials and outcomes impacting patient care;
  • Increase awareness of novel cancer treatments, molecular targets and approaches with practice-changing potential.

Atlantic Health System designates this live educational activity for a maximum of 4 AMA PRA Category 1 credits,  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  Atlantic Health System is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.

The registration deadline is June 26, 2020.  To register, email